Pharmaceuticals Market Research Reports & Industry Analysis

Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.

The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.

The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.

Found 17998 publications
Success in Value Added Services US$ 695.00

... create services to deliver these results for your business? Find out in Success in Value Added Services. Click here to view the sample pages Through expert insights, Success in Value Added Services unravels step-by-step details on how to build Value Added Services into your value proposition ...

Jun, 2016
Orphan Drug Commercialisation and Market Access in Emerging Markets US$ 695.00

Market access for orphan drugs: Can your company break through in emerging markets? Find out which emerging markets offer the best investment prospects for orphan drug ... America Market Access Director, Leading Orphan Drug Company International Marketing Director, Europe-based orphan drug manufacturer Market Access Director, Rare Cancers-focused Biopharmaceutical Company Orphan Disease ...

Jul, 2016
Orphan Drug Commercial Models: Sustaining the rare disease business US$ 695.00

... a part, so which model is best and what are the considerations which underpin that choice? This report analyses current orphan drug commercial models, assesses their ... for orphan drugs commercial teams to ensure that their business model works for all stakeholders? Key components: What are the key components of current commercial models ...

May, 2016
RAR-Related Orphan Receptor Gamma (RORγ) Modulators, Pipeline Insights, 2016 US$ 1,250.00

... about pipeline drugs across this mechanism of action. The Report gives insights on 20+ products, 18+ companies that are active in this field and 10+ ... Gamma (RORγ) Modulators based pipeline on the basis of target, MOA, route of administration, technology involved and molecule type Pipeline products coverage ...

Jul, 2016 80 pages
Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2016 US$ 1,950.00

... route of administration and molecule type, along with product development activities Highlights of licensing & collaboration opportunities and funding details Highlights of latest Microbiome technologies and innovative ...

Jul, 2016 170 pages
Mammalian Target of Rapamycin (Mtor) Inhibitors, Pipeline Insights, 2016 US$ 1,250.00

... target, MOA, route of administration, technology involved and molecule type. The report reviews key players involved in the therapeutics development for Mammalian Target of Rapamycin ...

Jul, 2016 100 pages
Janus Kinase Inhibitor (JAK) Inhibitors- Competitive Landscape, Technology and Pipeline Analysis, 2016 US$ 1,750.00

... market in near future. This report also has market analysis that covers various deals, agreements, collaborations, acquisitions between various pharma ... marketed and pipeline drugs. The report provides drug profile which includes product description, MOA, licensors & collaborators ...

Jul, 2016 103 pages
Global Pharmaceuticals and Healthcare Report Q3 2016 US$ 1,295.00

... View: Pharmaceutical companies will face an increasing number of external risks to their operations. Many of these new challenges emanate from the global financial ... (EUR937bn) global pharmaceutical market is forecast to post a 5.1% compound annual growth rate (CAGR) through to 2020. The USD7,355bn (EUR6,6631bn) global healthcare market is forecast ...

Jul, 2016 32 pages
Europe Pharmaceuticals and Healthcare Report Q3 2016 US$ 1,295.00

... 3 FREE quarterly updates BMI View: Europe will remain the most attractive region for multinational pharmaceutical firms over the coming years ... . Healthcare: USD1,844bn in 2015 to USD1,812bn in 2016; -1.7% in US dollar terms. Risk/Reward Index In BMI's Q316 Pharmaceuticals Risk/Reward Index (RRI), Europe scores ...

Jul, 2016 35 pages
Asia Pharmaceuticals and Healthcare Report Q3 2016 US$ 1,295.00

... compared to 3% globally over the next five years. Economically, South East Asia is set to be a particular bright spot. To fully leverage ... Healthcare: USD1,576bn in 2015 to USD1,662bn by 2016; a 5.4% y-o-y increase in US dollar terms. Risk/Reward Index In BMI's Pharmaceutical Q316 RRI, the Asia Pacific ...

Jul, 2016 32 pages
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016 US$ 3,500.00

... Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016’, provides in depth analysis on Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase ...

Jun, 2016 138 pages
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline... US$ 3,500.00

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface ...

Jun, 2016 111 pages
P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) The report reviews P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) targeted therapeutics under ...

Jun, 2016 52 pages
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016 US$ 3,500.00

... Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics under development ...

Jun, 2016 128 pages
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016 US$ 3,500.00

... CD274) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016’, provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted pipeline therapeutics ...

Jun, 2016 158 pages
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) -... US$ 3,500.00

... Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) The report reviews Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase ...

Jun, 2016 116 pages
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016 US$ 3,500.00

... GPRC1B or MGLUR2) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016’, provides in depth analysis on Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted pipeline therapeutics ...

Jun, 2016 54 pages
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H1 2016 US$ 3,500.00

... Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development ...

Jun, 2016 54 pages
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016 US$ 3,500.00

... Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016’, provides in depth analysis on Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted pipeline therapeutics ...

Jun, 2016 110 pages
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics under development ...

Jun, 2016 92 pages
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016 US$ 3,500.00

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016’, provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted pipeline therapeutics ...

Jun, 2016 67 pages
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2 ...

Jun, 2016 81 pages
Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Review, H1 2016 US$ 3,500.00

... Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Review, H1 2016’, provides in depth analysis on Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted pipeline therapeutics. The report provides comprehensive information on the Glycogen Synthase Kinase 3 Beta (GSK-3 Beta ...

Jun, 2016 61 pages
Gamma Secretase (EC 3.4.23.46) - Pipeline Review, H1 2016 US$ 3,500.00

... Secretase (EC 3.4.23.46) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Gamma Secretase (EC 3.4.23.46) - Pipeline Review, H1 2016’, provides in depth analysis on Gamma Secretase (EC 3.4.23.46) targeted pipeline therapeutics. The report provides comprehensive information on the Gamma Secretase ...

Jun, 2016 72 pages
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or... US$ 3,500.00

... Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) The report reviews C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor ...

Jun, 2016 116 pages
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016 US$ 3,500.00

... Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016’, provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted pipeline therapeutics. The report provides comprehensive information on the Coagulation Factor ...

Jun, 2016 53 pages
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016 US$ 3,500.00

... ‘CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016’, provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily ...

Jun, 2016 65 pages
Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016 US$ 3,500.00

... Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted pipeline therapeutics. The report provides comprehensive information on the Cathepsin B (APP Secretase or Cathepsin ...

Jun, 2016 41 pages
Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016 US$ 3,500.00

... Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016’, provides in depth analysis on Catenin Beta-1 (Beta Catenin or CTNNB1) targeted pipeline therapeutics. The report provides comprehensive information on the Catenin Beta-1 (Beta Catenin or CTNNB1), targeted therapeutics ...

Jun, 2016 58 pages
Apolipoprotein E (ApoE) - Pipeline Review, H1 2016 US$ 3,500.00

... Apolipoprotein E (ApoE) - Pipeline Review, H1 2016’, provides in depth analysis on Apolipoprotein E (ApoE) targeted pipeline therapeutics. The report provides comprehensive information on the Apolipoprotein E (ApoE) , targeted therapeutics, complete with analysis by indications, stage of development ...

Jun, 2016 45 pages
20s Proteasome - Pipeline Review, H1 2016 US$ 3,500.00

20s Proteasome - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘20s Proteasome - Pipeline Review, H1 2016’, provides in depth analysis on 20s Proteasome targeted pipeline therapeutics. The report provides comprehensive information on the 20s Proteasome , targeted therapeutics ...

Jun, 2016 70 pages
Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline US$ 2,995.00

Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline Summary GBI Research’s latest report, 'Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline' is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical ...

Jun, 2016 70 pages
Psoriasis - US Drug Forecast and Market Analysis to 2024 US$ 4,995.00

Psoriasis - US Drug Forecast and Market Analysis to 2024 SUMMARY Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder ... , Psoriasis causes tremendous morbidity and personal angst for patients. GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast ...

Apr, 2016 213 pages
Psoriasis - Japan Drug Forecast and Market Analysis to 2024 US$ 4,995.00

Psoriasis - Japan Drug Forecast and Market Analysis to 2024 SUMMARY Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder ... forecast for the top drugs in Japan from 2014-2024. Analysis of the impact of key events as well the drivers and restraints affecting Japan Psoriasis market ...

Apr, 2016 210 pages
Psoriasis - India Drug Forecast and Market Analysis to 2024 US$ 4,995.00

Psoriasis - India Drug Forecast and Market Analysis to 2024 SUMMARY Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder ... forecast for the top drugs in India from 2014-2024. Analysis of the impact of key events as well the drivers and restraints affecting India Psoriasis market ...

Apr, 2016 208 pages
Psoriasis - 5EU Drug Forecast and Market Analysis to 2024 US$ 6,995.00

Psoriasis - 5EU Drug Forecast and Market Analysis to 2024 SUMMARY Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder ... forecast for the top drugs in 5EU from 2014-2024. Analysis of the impact of key events as well the drivers and restraints affecting 5EU Psoriasis market ...

Apr, 2016 213 pages
Gastric and Gastroesophageal Junction Adenocarcinoma - US Drug Forecast and Market Analysis to 2024 US$ 4,995.00

Gastric and Gastroesophageal Junction Adenocarcinoma - US Drug Forecast and Market Analysis to 2024 SUMMARY Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth ...

Dec, 2015 267 pages
Gastric and Gastroesophageal Junction Adenocarcinoma - Japan Drug Forecast and Market Analysis to 2024 US$ 4,995.00

Gastric and Gastroesophageal Junction Adenocarcinoma - Japan Drug Forecast and Market Analysis to 2024 SUMMARY Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth ... added to chemotherapy regimens since 2010 and 2014, respectively. Japan represented the largest gastric cancer market in the 8MM in 2014 due to the ...

Dec, 2015 269 pages
Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players US$ 2,995.00

Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players SUMMARY GlobalData has released its pharma report, “Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players”. The ... with in-depth analysis on the companies in the rapidly growing Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) Market. The report identifies and analyses the key ...

Dec, 2015 122 pages
Gastric and Gastroesophageal Junction Adenocarcinoma - China Drug Forecast and Market Analysis to 2024 US$ 4,995.00

Gastric and Gastroesophageal Junction Adenocarcinoma - China Drug Forecast and Market Analysis to 2024 SUMMARY Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth ... as an overview on the competitive landscape. Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT ...

Dec, 2015 270 pages
Gastric and Gastroesophageal Junction Adenocarcinoma - 5EU Drug Forecast and Market Analysis to 2024 US$ 6,995.00

Gastric and Gastroesophageal Junction Adenocarcinoma - 5EU Drug Forecast and Market Analysis to 2024 SUMMARY Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the ...

Dec, 2015 283 pages
Global and Chinese Vitamin Industry, 2016 Market Research Report US$ 2,800.00

... 'Global and Chinese Vitamin Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Vitamin industry with a focus on the Chinese market ... a new project of Vitamin Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Vitamin industry covering all important ...

Jul, 2016 150 pages
Global and Chinese Recombinant Protein Drug Industry, 2016 Market Research Report US$ 2,800.00

The 'Global and Chinese Recombinant Protein Drug Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Recombinant Protein Drug ... project of Recombinant Protein Drug Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Recombinant Protein Drug industry ...

Jul, 2016 150 pages
Global and Chinese Pharmaceuticals RFID Industry, 2016 Market Research Report US$ 2,800.00

The 'Global and Chinese Pharmaceuticals RFID Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Pharmaceuticals RFID industry with a focus on the Chinese ...

Jul, 2016 150 pages
Global and Chinese Pharmaceutical Grade Calcium Carbonate Industry, 2016 Market Research Report US$ 2,800.00

... 'Global and Chinese Pharmaceutical Grade Calcium Carbonate Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Pharmaceutical Grade Calcium ... project of Pharmaceutical Grade Calcium Carbonate Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Pharmaceutical Grade Calcium ...

Jul, 2016 150 pages
Global and Chinese Pharmaceutical Glass Packaging Industry, 2016 Market Research Report US$ 2,800.00

The 'Global and Chinese Pharmaceutical Glass Packaging Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Pharmaceutical Glass Packaging ... project of Pharmaceutical Glass Packaging Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Pharmaceutical Glass Packaging industry ...

Jul, 2016 150 pages
Global and Chinese Pharmaceutical Equipment Industry, 2016 Market Research Report US$ 2,800.00

The 'Global and Chinese Pharmaceutical Equipment Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Pharmaceutical Equipment industry with a focus on the Chinese ...

Jul, 2016 150 pages
Global and Chinese Pharmaceutical Distribution Industry, 2016 Market Research Report US$ 2,800.00

The 'Global and Chinese Pharmaceutical Distribution Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Pharmaceutical Distribution industry with a focus on the Chinese ...

Jul, 2016 150 pages
Global and Chinese Pharmaceutical Chain Industry, 2016 Market Research Report US$ 2,800.00

The 'Global and Chinese Pharmaceutical Chain Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Pharmaceutical Chain industry with a focus on the Chinese ...

Jul, 2016 150 pages
Global and Chinese Pharmaceutical Blister Packaging Industry, 2016 Market Research Report US$ 2,800.00

The 'Global and Chinese Pharmaceutical Blister Packaging Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Pharmaceutical Blister Packaging ... project of Pharmaceutical Blister Packaging Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Pharmaceutical Blister Packaging industry ...

Jul, 2016 150 pages
1 2 3 4 5 >
Skip to top